These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28719060)

  • 41. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.
    Todesco E; Day N; Amiel C; Elaerts S; Schneider V; Roudière L; Hué S; Liotier JY; Bottero J; L'Yavanc T; Ohayon M; Gosset D; Thibault V; Surgers L; Chas J; Akhavan S; Velter A; Katlama C; Kreplak G; Marcelin AG; Valantin MA
    Int J Antimicrob Agents; 2019 May; 53(5):678-681. PubMed ID: 30742957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users.
    Monga N; Rehm J; Fischer B; Brissette S; Bruneau J; El-Guebaly N; Noël L; Tyndall M; Wild C; Leri F; Fallu JS; Bahl S
    Drug Alcohol Depend; 2007 Apr; 88(1):1-8. PubMed ID: 17049753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents.
    Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J
    Liver Int; 2014 Sep; 34(8):1198-206. PubMed ID: 24164865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.
    Harrell PT; Mancha BE; Petras H; Trenz RC; Latimer WW
    Drug Alcohol Depend; 2012 May; 122(3):220-7. PubMed ID: 22030276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.
    Grebely J; Lima VD; Marshall BD; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E
    PLoS One; 2014; 9(6):e97726. PubMed ID: 24897109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort.
    Cox J; Maurais E; Hu L; Moodie EE; Law S; Bozinoff N; Potter M; Rollet K; Hull M; Tyndall M; Cooper C; Gill J; Saeed S; Klein MB;
    Drug Alcohol Depend; 2014 Apr; 137():121-8. PubMed ID: 24559606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing.
    Caro-Pérez N; Martínez-Rebollar M; Gregori J; Quer J; González P; Gambato M; García-González N; González-Candelas F; Costa J; Esteban JI; Mallolas J; Forns X; Laguno M; Pérez-Del-Pulgar S
    J Clin Virol; 2017 Jul; 92():42-47. PubMed ID: 28521213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
    Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user.
    Aitken CK; Tracy SL; Revill P; Bharadwaj M; Bowden DS; Winter RJ; Hellard ME
    J Clin Virol; 2008 Apr; 41(4):293-6. PubMed ID: 18242125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of hepatitis C virus (HCV) infection in drug substitution programs.
    Witteck A; Schmid P; Hensel-Koch K; Thurnheer MC; Bruggmann P; Vernazza P;
    Swiss Med Wkly; 2011; 141():w13193. PubMed ID: 21623473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.
    Hayashi K; Wood E; Kerr T; Dong H; Nguyen P; Puskas CM; Guillemi S; Montaner JS; Milloy MJ
    BMC Infect Dis; 2016 Aug; 16(1):455. PubMed ID: 27568002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HCV infection among cocaine users in the state of Pará, Brazilian Amazon.
    Oliveira-Filho AB; Sawada L; Pinto LC; Locks D; Bahia SL; Brasil-Costa I; Lemos JA
    Arch Virol; 2013 Jul; 158(7):1555-60. PubMed ID: 23408127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predominance of hepatitis C virus genotype 4 infection and rapid transmission between 1935 and 1965 in the Central African Republic.
    Njouom R; Frost E; Deslandes S; Mamadou-Yaya F; Labbé AC; Pouillot R; Mbélesso P; Mbadingai S; Rousset D; Pépin J
    J Gen Virol; 2009 Oct; 90(Pt 10):2452-2456. PubMed ID: 19535500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots.
    Hope VD; Hickman M; Ngui SL; Jones S; Telfer M; Bizzarri M; Ncube F; Parry JV
    J Viral Hepat; 2011 Apr; 18(4):262-70. PubMed ID: 20456636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.
    Lamoury FM; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL
    PLoS One; 2015; 10(7):e0131437. PubMed ID: 26192190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort.
    Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M
    Health Sci Rep; 2022 Sep; 5(5):e719. PubMed ID: 36000082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.
    Danta M; Brown D; Bhagani S; Pybus OG; Sabin CA; Nelson M; Fisher M; Johnson AM; Dusheiko GM;
    AIDS; 2007 May; 21(8):983-91. PubMed ID: 17457092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombination in hepatitis C virus is not uncommon among people who inject drugs in Kolkata, India.
    Gupta D; Saha K; Biswas A; Firdaus R; Ghosh M; Sadhukhan PC
    Infect Genet Evol; 2017 Mar; 48():156-163. PubMed ID: 27923769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005.
    Micalessi MI; Gérard C; Ameye L; Plasschaert S; Brochier B; Vranckx R
    J Med Virol; 2008 Apr; 80(4):640-5. PubMed ID: 18297717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.